title: Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients.
abstract: Fifteen patients with advanced non-small cell lung cancer, already treated with first-line chemotherapy, entered a protocol of palliative second-line treatment with the hemysynthetic vinca alkaloid vinorelbine (25 mg/sm weekly for two months). No patient obtained an objective response and the trial was stopped. Toxicity was not as mild as expected, with one treatment-related death due to leukopenia. It is concluded that single-agent vinorelbine, although effective as front-line chemotherapy for non-small cell lung cancer patients, is probably not suitable for palliative treatment of pretreated patients.
authors.affiliation: U.O. Oncologia Medica, Ospedale S. Andrea, La Spezia, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Pronzato
authors.forename: M
authors.initials: M
authors.lastname: Landucci
authors.forename: F
authors.initials: F
authors.lastname: Vaira
authors.forename: A
authors.initials: A
authors.lastname: Vigani
authors.forename: G
authors.initials: G
authors.lastname: Bertelli
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D000970:Antineoplastic Agents; D014747:Vinblastine; D000077235:Vinorelbine